Fig. 2
From: Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice
Effect of EsV3 treatment on body weight and feeding. A. Body weight of EsV3 in hyperlipidemic mice (n = 8). B. Body weight of EsV3 in hyperlipidemic mice at 16 weeks (n = 8). C. Effect of EsV3 on feeding in hyperlipidemic mice (n = 8). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. model group. & p < 0.05, && p < 0.01, &&& p < 0.001 vs. atorvastatin. For comparisons involving multiple groups, a one-way ANOVA was performed